Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Nausea 2Vomiting 1Parasomnias 1Pain 1Neoplasms 1Marijuana Abuse 1Dysgeusia 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Cachexia 1Breast Neoplasms 1Behavior 1Arthralgia 1Appetitive Behavior 1Anxiety Disorders 1

Interventions

Fentanyl 19Analgesia 15Acupuncture Therapy 13Oxycodone 12Zoledronic Acid 11Surveys and Questionnaires 10nabiximols 9Therapeutics 9Morphine 9Acetaminophen 9Psychiatric Rehabilitation 8Ketamine 8Hydromorphone 7Lidocaine 6Ibandronic Acid 6Radiotherapy 5Early Intervention, Educational 5Bupivacaine 5Analgesics, Opioid 5Yoga 4Transcutaneous Electric Nerve Stimulation 4Therapeutic Touch 4Ropivacaine 4Music Therapy 4Methadone 4Massage 4Aromatherapy 4alvimopan 3Tapentadol 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pain × Cannabidiol × Clear all
NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed
91 enrolled

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡